These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30107034)

  • 21. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A note on breast cancer trials with pCR-based accelerated approval.
    Xia Y; Cui L; Yang B
    J Biopharm Stat; 2014; 24(5):1102-14. PubMed ID: 24926729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval.
    Djulbegovic B; Glasziou P; Klocksieben FA; Reljic T; VanDenBergh M; Mhaskar R; Ioannidis JPA; Chalmers I
    J Clin Epidemiol; 2018 Jun; 98():24-32. PubMed ID: 29432860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New paradigm for drug developments--from emerging market statistical perspective.
    Quan H; Chen X; Zhang J; Zhao PL
    Contemp Clin Trials; 2013 Nov; 36(2):697-703. PubMed ID: 23810938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conceptual framework and systematic review of the effects of participants' and professionals' preferences in randomised controlled trials.
    King M; Nazareth I; Lampe F; Bower P; Chandler M; Morou M; Sibbald B; Lai R
    Health Technol Assess; 2005 Sep; 9(35):1-186, iii-iv. PubMed ID: 16153352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.
    Peck CC; Rubin DB; Sheiner LB
    Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358
    [No Abstract]   [Full Text] [Related]  

  • 30. Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
    Philips Z; Ginnelly L; Sculpher M; Claxton K; Golder S; Riemsma R; Woolacoot N; Glanville J
    Health Technol Assess; 2004 Sep; 8(36):iii-iv, ix-xi, 1-158. PubMed ID: 15361314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ethical pitfalls in neonatal comparative effectiveness trials.
    Modi N
    Neonatology; 2014; 105(4):350-1. PubMed ID: 24931328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generalizing results of randomized trials to clinical practice: reliability and cautions.
    Flather M; Delahunty N; Collinson J
    Clin Trials; 2006; 3(6):508-12. PubMed ID: 17170034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is Scientific Medical Literature Related to Endometriosis Treatment Evidence-Based? A Systematic Review on Methodological Quality of Randomized Clinical Trials.
    Capraş RD; Urda-Cîmpean AE; Bolboacă SD
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31311075
    [No Abstract]   [Full Text] [Related]  

  • 34. First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF.
    Zile MR; Abraham WT; Lindenfeld J; Weaver FA; Zannad F; Graves T; Rogers T; Galle EG
    Am Heart J; 2018 Oct; 204():139-150. PubMed ID: 30118942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ethics of Informed Consent for Pragmatic Trials with New Interventions.
    Kalkman S; Kim SYH; van Thiel GJMW; Grobbee DE; van Delden JJM
    Value Health; 2017; 20(7):902-908. PubMed ID: 28712619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Systematic review on methodology of randomized controlled trials of post-marketing Chinese patent drugs for treatment of type 2 diabetes].
    Ma LX; Wang YY; Li XX; Liu JP
    Zhong Xi Yi Jie He Xue Bao; 2012 Mar; 10(3):279-92. PubMed ID: 22409917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.
    Naci H; Wouters OJ; Gupta R; Ioannidis JPA
    Milbank Q; 2017 Jun; 95(2):261-290. PubMed ID: 28589600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges of randomized controlled surgical trials.
    Campbell AJ; Bagley A; Van Heest A; James MA
    Orthop Clin North Am; 2010 Apr; 41(2):145-55. PubMed ID: 20399354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How to generalize efficacy results of randomized trials: recommendations based on a systematic review of possible approaches.
    Post PN; de Beer H; Guyatt GH
    J Eval Clin Pract; 2013 Aug; 19(4):638-43. PubMed ID: 22862884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.